AbbVie
ABBV
2,021 hedge funds and large institutions have $76.1B invested in AbbVie in 2019 Q2 according to their latest regulatory filings, with 125 funds opening new positions, 905 increasing their positions, 762 reducing their positions, and 113 closing their positions.
19% more repeat investments, than reductions
Existing positions increased: 905 | Existing positions reduced: 762
11% more first-time investments, than exits
New positions opened: 125 | Existing positions closed: 113
0.08% less ownership
Funds ownership: 69.63% → 69.55% (-0.08%)
1% less funds holding
Funds holding: 2,034 → 2,021 (-13)
2% less call options, than puts
Call options by funds: $1.41B | Put options by funds: $1.43B
8% less capital invested
Capital invested by funds: $82.8B → $76.1B (-$6.76B)
15% less funds holding in top 10
Funds holding in top 10: 61 → 52 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.06B |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$713M |
| 3 |
BlackRock
New York
|
+$244M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$232M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$183M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$2.86B |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$770M |
| 3 |
Capital International Investors
Los Angeles,
California
|
-$475M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$293M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$160M |
ABBV Hedge Fund Activity: Q2 2019 in Review
2,021 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q2 2019, worth a combined $76.1B — down 8.2% from $82.8B a quarter earlier.
Buyers outnumbered sellers: 125 funds opened new ABBV positions and 113 closed out — a net gain of 12 holders — while 905 added to existing stakes and 762 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $1.06B. The largest seller was Capital Research Global Investors, cutting an estimated $2.86B.
- 2,021 institutional investors held AbbVie (ABBV) as of Q2 2019, down from 2,034 in Q1 2019.
- Funds reported $76.1B of AbbVie stock for Q2 2019, down 8.2% quarter-over-quarter.
- 125 funds opened new AbbVie positions in Q2 2019 and 113 closed out, a net change of +12 holders.
- The largest AbbVie buyer in Q2 2019 was Fidelity Investments, an estimated $1.06B added.
- The largest AbbVie seller in Q2 2019 was Capital Research Global Investors, an estimated $2.86B sold.
Based on aggregated 13F filings for Q2 2019.